Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 9/20 | 0.42 |
| ▸ | MAOA | P21397 | 7/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19966793 | 0.92 | KDM1A (0.43) | KMT2AKDM1AMAOARCOR1KDM1B | |
| SCHEMBL31726363 | 0.85 | EPHX2 (0.41) | KMT2AKDM1ARCOR1EPHX2 | |
| SCHEMBL2217435 | 0.84 | KMT2A (0.49) | KMT2A | |
| SCHEMBL30692466 | 0.84 | KMT2A (0.49) | KMT2A | |
| SCHEMBL30688518 | 0.84 | KMT2A (0.49) | KMT2A | |
| SCHEMBL23138613 | 0.84 | KMT2A (0.49) | KMT2A | |
| SCHEMBL30129745 | 0.84 | KMT2A (0.50) | KMT2AEPHX2 | |
| SCHEMBL8271888 | 0.84 | KMT2A (0.50) | KMT2AEPHX2 | |
| SCHEMBL30133594 | 0.84 | KMT2A (0.50) | KMT2AEPHX2 | |
| SCHEMBL19960955 | 0.84 | KMT2A (0.50) | KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | PROMEGA CORPORATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316070-B2 | Dual protected pro-coelenterazine substrates | SI, GLB1, CTRL | KMT2A 3495/4885KDM1A 4100/4885MAOA 1733/4885 |
| US-20180072781-A1 | DUAL PROTECTED PRO-COELENTERAZINE SUBSTRATES | SI, GLB1, PREP | KMT2A 2976/4885KDM1A 4011/4885MAOA 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.